Invasive hydatidiform mole

Summary

Invasive hydatidiform mole (MONDO:0020549) is a disease and 1 clinical trial. Top therapeutic interventions include dactinomycin and leucovorin. A subtype of hydatidiform mole — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 2
• Clinical trials: 1

Clinical features

Signs & symptoms

Clinical features (HPO)

2 HPO clinical features (Orphanet curated; top 2 by frequency):

HPO ID	Term	Frequency
HP:0011433	High maternal serum chorionic gonadotropin	Very frequent (80-99%)
HP:0400008	Menometrorrhagia	Very frequent (80-99%)

Identifiers

Disease identifiers

Field	Value
Canonical name	invasive hydatidiform mole
Mondo ID	MONDO:0020549
MeSH	D002820
Orphanet	99925
NCIT	C6985
SNOMED CT	416669000
UMLS	C0008493
MedGen	3055
GARD	0019711
Is cancer (heuristic)	no

Also known as: chorioadenoma · chorioadenoma Destruens · chorioadenoma destruens · IHM · invasive gestational trophoblastic neoplasm · invasive hydatidiform Mole · invasive hydatidiform mole · invasive Mole

Disease family

This is a subtype of hydatidiform mole. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › trophoblastic neoplasm › hydatidiform mole › invasive hydatidiform mole

Related subtypes (4): complete hydatidiform mole, partial hydatidiform mole, hydatidiform mole, recurrent, 3, hydatidiform mole, recurrent, 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04562558	Not specified	ACTIVE_NOT_RECRUITING	Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACTINOMYCIN	4	1
LEUCOVORIN	4	1
CHEMBL4748391	0	1